相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。FLT3-ITD and TLR9 use Bruton tyrosine kinase to activate distinct transcriptional programs mediating AML cell survival and proliferation
Thomas Oellerich et al.
BLOOD (2015)
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)
Jennifer A. Woyach et al.
BLOOD (2014)
Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia
Stuart A. Rushworth et al.
BLOOD (2014)
Treatment With FLT3 Inhibitor in Patients With FLT3-Mutated Acute Myeloid Leukemia Is Associated With Development of Secondary FLT3-Tyrosine Kinase Domain Mutations
Yesid Alvarado et al.
CANCER (2014)
SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia
Alexandre Puissant et al.
CANCER CELL (2014)
FLT3 Kinase Inhibitor TTT-3002 Overcomes Both Activating and Drug Resistance Mutations in FLT3 in Acute Myeloid Leukemia
Hayley S. Ma et al.
CANCER RESEARCH (2014)
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ibrutinib, Obinutuzumab, Idelalisib, and Beyond: Review of Novel and Evolving Therapies for Chronic Lymphocytic Leukemia
Clement Chung et al.
PHARMACOTHERAPY (2014)
Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma
Scott A. Ezell et al.
ONCOTARGET (2014)
Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML
Lyubov Zaitseva et al.
ONCOTARGET (2014)
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Jason A. Dubovsky et al.
BLOOD (2013)
BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-kappa B
Stuart A. Rushworth et al.
CELLULAR SIGNALLING (2013)
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The high Nrf2 expression in human acute myeloid leukemia is driven by NF-κB and underlies its chemo-resistance
Stuart A. Rushworth et al.
BLOOD (2012)
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma
Yu-Tzu Tai et al.
BLOOD (2012)
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C. Smith et al.
NATURE (2012)
The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils
Fumiko Honda et al.
NATURE IMMUNOLOGY (2012)
Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia
Katja Fiedler et al.
BLOOD (2011)
Bruton's Tyrosine Kinase Is Required for TLR-Dependent Heme Oxygenase-1 Gene Activation via Nrf2 in Macrophages
Vijith Vijayan et al.
JOURNAL OF IMMUNOLOGY (2011)
Survey of Activated FLT3 Signaling in Leukemia
Ting-lei Gu et al.
PLOS ONE (2011)
FLT3 as a therapeutic target in AML: still challenging after all these years
Thomas Kindler et al.
BLOOD (2010)
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
Gunnar Juliusson et al.
BLOOD (2009)
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
Patrick P. Zarrinkar et al.
BLOOD (2009)
Proteomic and Genetic Approaches Identify Syk as an AML Target
Cynthia K. Hahn et al.
CANCER CELL (2009)
Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain
Abdalla J. Mohamed et al.
IMMUNOLOGICAL REVIEWS (2009)
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
Richard F. Schlenk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
A critical role for Lyn in acute myeloid leukemia
Ceric Dos Santos et al.
BLOOD (2008)
The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases
Steven Knapper et al.
BLOOD (2006)
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors
Mark Levis et al.
BLOOD (2006)
Bruton's tyrosine kinase is required for TLR2 and TLR4-Induced TNF, but not IL-6, production
Nicole J. Horwood et al.
JOURNAL OF IMMUNOLOGY (2006)
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain
F Heidel et al.
BLOOD (2006)
Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells
N Feldhahn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential:: A revised road map for adult blood lineage commitment
J Adolfsson et al.
CELL (2005)
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
RM Stone et al.
BLOOD (2005)
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
BD Smith et al.
BLOOD (2004)
Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia
T Matsunaga et al.
NATURE MEDICINE (2003)
Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia
S Meshinchi et al.
BLOOD (2003)
Survival of acute myeloid leukemia cells requires PI3 kinase activation
Q Xu et al.
BLOOD (2003)
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia:: association with FAB subtypes and identification of subgroups with poor prognosis
C Thiede et al.
BLOOD (2002)
Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts
KU Birkenkamp et al.
LEUKEMIA (2001)
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Y Yamamoto et al.
BLOOD (2001)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
BLNK mediates Syk-dependent Btk activation
Y Baba et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Bruton's tyrosine kinase is required for activation of IκB kinase and nuclear factor κB in response to B cell receptor engagement
JB Petro et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
